Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mark Kronenfeld Insider Profile
4 Followers
Mark Kronenfeld, Director at Pacira Pharmaceuticals, holds 19.67K shares in Pacira Pharmaceuticals (Ticker: PCRX).
Mark Kronenfeld Pacira Pharmaceuticals (PCRX)Director
Pacira Pharmaceuticals (PCRX)
Director
Ranked #62,970 out of 98,624 Corporate Insiders
Profitable Transactions
2 out of 4 Profitable Transactions
Average Return
-8.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Mark Kronenfeld's holdings
Insider Roles
Director
Roles that Mark Kronenfeld holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Nov 13, 2017 - Nov 13, 2018
Return:+11.90%
The most profitable trade made by Mark Kronenfeld
Mark Kronenfeld's Trading History
List of latest transactions for each holding click on a transaction to see Mark Kronenfeld's performance on stock
You May Also Like
Mark Kronenfeld insider profile FAQ
What is the percentage of profitable transactions made by Mark Kronenfeld?
The percentage of profitable transactions made by Mark Kronenfeld is 50%.
What is the average return per transaction made by Mark Kronenfeld?
The average return per transaction made by Mark Kronenfeld is -8.80%.
What stocks does Mark Kronenfeld hold?
Mark Kronenfeld holds: PCRX stocks.
What was Mark Kronenfeld’s latest transaction?
Mark Kronenfeld latest transaction was an Uninformative Buy of ―.
What was Mark Kronenfeld's most profitable transaction?
Mark Kronenfeld’s most profitable transaction was an Informative Buy of PCRX stock on November 13, 2017. The return on the trade was 11.90%.
What is Mark Kronenfeld's role in Pacira Pharmaceuticals?
Mark Kronenfeld's role in Pacira Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.